Correlation between KRAS mutations and clinicopathologic features in colorectal carcinomas.
- VernacularTitle:结直肠癌KRAS基因突变与临床病理特征的关系
- Author:
Jie GAO
1
;
Jing ZHANG
;
Tao LU
;
Xiao-yuan LI
;
Ning JIA
;
Zhi-yong LIANG
Author Information
- Publication Type:Journal Article
- MeSH: Adenocarcinoma; genetics; pathology; Adenocarcinoma, Mucinous; genetics; pathology; Adult; Aged; Aged, 80 and over; Codon; Colorectal Neoplasms; genetics; pathology; DNA Mutational Analysis; Female; Genotype; Humans; Liver Neoplasms; genetics; secondary; Male; Middle Aged; Mutation; Ovarian Neoplasms; genetics; secondary; Proto-Oncogene Proteins; genetics; Proto-Oncogene Proteins p21(ras); Sex Factors; Young Adult; ras Proteins; genetics
- From: Chinese Journal of Pathology 2012;41(9):595-598
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate mutations of KRAS gene and clinicopathological characteristics of colorectal carcinomas (CRC) in Chinese.
METHODSTumor cells were collected by microdissection from paraffin-embedded tumor specimens and adjacent normal colon tissues from 167 CRC patients. Genomic DNA was extracted and mutations of KRAS gene (codons 12 and 13) were detected by scorpions amplification refractory mutation system (Scorpions ARMS).
RESULTSKRAS mutations were identified in 66 patients (39.5%), including G13D (21 cases, 12.6%), G12D (15 cases, 9.0%), G12V (13 cases, 7.8%), G12C (6 cases, 3.6%), G12A (5 cases, 3.0%), G12S (4 cases, 2.4%) and G12R (2 cases, 1.2%). Female patients had a higher KRAS mutation rate than male (50.0%, 29/58 vs.33.9%, 37/109, P < 0.05). However, KRAS mutations did not correlate with the patient age, tumor sites, histological types and grades (P > 0.05). Additionally, 7 of 18 patients with metastatic CRC had KRAS gene mutations. Overall, KRAS gene mutation was identified in 59 patients among 149 primary CRC (39.6%). There was no significant difference in KRAS mutation between primary and metastatic tumors (P > 0.05).
CONCLUSIONSThe detection rate of KRAS mutation is higher in female CRC patients than the males. The presence of KRAS mutation does not significantly correlate with the patients' age, tumor site, differentiation grades and histological types. There was no significant difference in KRAS mutation between the primary and metastatic tumors.
